Appeal No. 95-2876
Application 07/906,403
reproductive organs to treat more than one
condition. Thus, for instance, monolithic
microparticles could be prepared and delivered
containing two different antibodies to passively
treat two different diseases. In fact, it may be
desirable under some circumstances to actively
immunize a patient against one disorder and
simultaneously passively immunize the patient
against a second disorder with antigen and antibody
delivered in the same microparticles.
The matrix materials employed to form the spherical
microparticle are preferably selected from "polyglycolic acid,
polylactic acid, as well as copolymers of glycolic and lactic
acid, and glycerol mono-and distearate." See column 12, lines
42-45. The preferred size of the microparticle ranges from 20
to 60 micrometer (micron) which implies that a pharmaceutical
agent incorporated therein is smaller than 60 or 20 microns.
Since the phrase "wherein said first polymer form as a solid
polymer core sphere not having drug as the core of the
polymeric core" in claim 20 is
14
Page: Previous 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 Next
Last modified: November 3, 2007